Citius Oncology, Inc. CTOR Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| —— | —— | ||
| —— | —— | ||
| —— | —— | ||
| $6.42M+30.3% | $4.93M+16.1% | ||
| $8.78M+7.8% | $8.15M+37.8% | ||
| $23.52M+14.3% | $20.57M+69.7% | ||
| -$23.52M-14.3% | -$20.57M— | ||
| —— | —— | ||
| -$181.66K-105% | $3.43M— | ||
| -$23.7M-15.2% | -$20.57M-69.7% | ||
| $1.06M+83.5% | $576K0.0% | ||
| -$24.76M-17.1% | -$21.15M-66.6% | ||
| -$0.34-9.7% | -$0.31-63.2% | ||
| -$23.52M-14.3% | -$20.57M-441% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Citius Oncology, Inc. profitable?
- Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.
- What is Citius Oncology, Inc.'s earnings per share?
- Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
- Where does Citius Oncology, Inc.'s income statement data come from?
- Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.